Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD
Journal
Chest
Journal Volume
163
Journal Issue
4
Pages
799
Date Issued
2023-04
Author(s)
Abstract
Researchers have yet to obtain conclusive evidence differentiating among fixed-dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) for COPD in terms of real-world clinical outcomes.
Subjects
COPD; acute exacerbation; cardiovascular event; fixed-dose combinations; long-acting muscarinic antagonists; long-acting β(2)-agonists
SDGs
Publisher
ELSEVIER
Type
journal article